Article Details
Retrieved on: 2025-01-03 17:51:12
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses an FDA order resolving a shortage of diabetes drugs, tirzepatide injection products (Mounjaro and Zepbound), by Eli Lilly. The FDA's role in managing GLP-1 receptor agonists, including safety and compounding concerns, is highlighted.
Article found on: www.jdsupra.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here